80795-53-5

Basic information

• Product Name: Methyl 3,5-di-O-benzyl-a-D-ribofuranoside
• Synonyms: Methyl 3,5-di-O-benzyl-a-D-ribofuranoside
• CAS NO: 80795-53-5
• Molecular Weight: 344.408
• EINECS: -0
• Mol File: 80795-53-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Methyl 3,5-di-O-benzyl-a-D-ribofuranoside(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3,5-di-O-benzyl-a-D-ribofuranoside(80795-53-5)
• EPA Substance Registry System: Methyl 3,5-di-O-benzyl-a-D-ribofuranoside(80795-53-5)

Safety Data

• Hazardous Substances Data: 80795-53-5(Hazardous Substances Data)

Usage

General Description

Methyl 3,5-di-O-benzyl-a-D-ribofuranoside is a chemical compound derived from ribofuranose, a component of ribonucleic acids (RNA) and other important biological molecules. It is synthesized by selectively protecting the 3- and 5-hydroxyl groups of ribofuranose with benzyl groups and then methylating the remaining hydroxyl group. Methyl 3,5-di-O-benzyl-a-D-ribofuranoside has potential applications in organic synthesis and medicinal chemistry, as well as in the study of the structure and function of ribofuranose-containing molecules in biological systems. Its structure and reactivity make it a valuable building block for creating new compounds and understanding the role of ribofuranose in various biochemical processes.

Upstream product

• 532-20-7 D-Ribose 
• 79083-29-7 (2R,3R,4R,5S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-methoxytetrahydrofuran 
• 52485-92-4 methyl α-D-ribofuranoside 
• 1824-96-0 methyl ribofuranoside 
• 64363-77-5 methyl 2,3,5-tri-O-benzyl-D-ribofuranoside 
• 75-24-1 trimethylaluminum 
• 100-44-7 benzyl chloride 

Downstream Products

• 885592-69-8 (2S,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-one 
• 1439900-71-6 (Z)-N-((2S,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-ylidene)-2-methylpropane-2-sulfinamide 
• 1255860-34-4 (2S)-butyl-2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxa-spiro[3.4]octan-7-yl)-methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1255860-32-2 1-[(4R,5R,7R,8R)-8-(benzyloxy)-7-(benzyloxy-methyl)-1,6-dioxaspiro[3.4]octan-5-yl]pyrimidine-2,4(1H,3H)-dione 
• 1255860-31-1 1-[(2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxy-methyl)-3-hydroxy-3-(2-hydroxyethyl)tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione 
• 1255860-30-0 1-((2R,3R,4R,5R)-3-allyl-4-(benzyloxy)-5-(benzyloxymethyl)-3-hydroxytetra-hydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1255860-29-7 (2S,3R,4R,5R)-3-allyl-4-(benzyloxy)-5-(benzyl-oxymethyl)-2-methoxytetrahydrofuran-3-yl benzoate 
• 1403250-97-4 (2S)-isopropyl 2-(((((2R,3S,4R,5R)-4-amino-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1439900-80-7 (2S)-isopropyl 2-(((2R,3S,4R,5R)-4-((tert-butoxycarbonyl)amino)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-O-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)(phenoxy)-phosohoryl)amino)propanoate 
• 1439900-77-2 1-((2R,3R,4S,5R)-3-amino-4-(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1439900-76-1 N-((2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-methyltetrahydrofuran-3-yl)-2,2,2-trifluoroacetamide 
• 1439900-73-8 N-((2S,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyltetrahydrofuran-3-yl)-2,2,2-trifluoroacetamide 
• 1439900-72-7 N-((2S,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyltetrahydrofuran-3-yl)-2-methylpropane-2-sulfinamide 
• 1439900-81-8 (2S)-isopropyl 2-(((((2R,3S,4R,5R)-4-amino-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 

Relevant articles and documents

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

Uracyl Spirooxetane Nucleoside Phosphoramidates

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate which inhibits the hepatitis C virus (HCV).

Synthesis and properties of triplex-forming oligonucleotides containing 2′-O-(2-methoxyethyl)-5-(3-aminoprop-1-ynyl)-uridine

2′-O-(2-Methoxyethyl)-5-(3-aminoprop-1-ynyl)-uridine phosphoramidite (MEPU) has been synthesized from d-ribose and 5-iodouracil and incorporated into triplex-forming oligonucleotides (TFOs) by automated solid-phase oligonucleotide synthesis. The TFOs gave very high triplex stability with their target duplexes as measured by ultraviolet/fluorescence melting and DNase I footprinting. The incorporation of MEPU into TFOs renders them resistant to degradation by serum nucleases.